Sangamo Biosciences, Inc. operates in the Biological products exc. diagnostic sector. Sangamo BioSciences, Inc. (Sangamo) is engaged in the research, development and commercialization of zinc finger deoxyribonucleic acid (DNA)-binding proteins (ZFPs), a naturally occurring class of proteins, and develop a technology platform. ZFPs can be engineered to make ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off, and ZFP nucleases (ZFNs), proteins that enable it to modify DNA sequences in a range of ways. The Company focuses on the development of human therapeutics and it is building a pipeline of ZFP Therapeutics. Its ZFP Therapeutic, SB-509, a plasmid formulation of a ZFP TF activator of the vascular endothelial growth factor-A (VEGF-A) gene, is under evaluation in a phase-IIb clinical trial for moderately severe diabetic neuropathy (DN). It has an ongoing phase-I/II clinical trial and two phase-I trials to evaluate the first therapeutic application of its ZFN technology, SB-728-T, for the treatment of human immunodeficiency virus (HIV). In our complete report available for purchase the company is compared to: Neurobiological Technologies, Inc., Trimeris Inc and Micromet, Inc..